Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum, Bilal Omer, Haruko Tashiro, et al.
Cancer Discovery (2017) Vol. 7, Iss. 11, pp. 1238-1247
Open Access | Times Cited: 243

Showing 1-25 of 243 citing articles:

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, et al.
Cell (2018) Vol. 175, Iss. 4, pp. 998-1013.e20
Open Access | Times Cited: 1617
The evolution of commercial drug delivery technologies
Ava M. Vargason, Aaron C. Anselmo, Samir Mitragotri
Nature Biomedical Engineering (2021) Vol. 5, Iss. 9, pp. 951-967
Open Access | Times Cited: 966
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson, Marcela V. Maus
Nature reviews. Cancer (2021) Vol. 21, Iss. 3, pp. 145-161
Open Access | Times Cited: 633
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner, Crystal L. Mackall
Nature Medicine (2019) Vol. 25, Iss. 9, pp. 1341-1355
Closed Access | Times Cited: 517
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong, Justin Clubb, Yvonne Y. Chen
Cancer Cell (2020) Vol. 38, Iss. 4, pp. 473-488
Open Access | Times Cited: 482
Programming CAR-T cells to kill cancer
Louai Labanieh, Robbie G. Majzner, Crystal L. Mackall
Nature Biomedical Engineering (2018) Vol. 2, Iss. 6, pp. 377-391
Open Access | Times Cited: 353
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 336
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, et al.
Molecular Therapy (2020) Vol. 28, Iss. 11, pp. 2320-2339
Open Access | Times Cited: 293
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 241
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner, Enrico Fritsche, Michael A. Pulsipher, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 379-393
Open Access | Times Cited: 205
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi, et al.
Cancer Immunology Research (2019) Vol. 8, Iss. 3, pp. 334-344
Open Access | Times Cited: 204
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 204
CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
Clare Y. Slaney, Pin Wang, Phillip K. Darcy, et al.
Cancer Discovery (2018) Vol. 8, Iss. 8, pp. 924-934
Closed Access | Times Cited: 201
CAR T cells for brain tumors: Lessons learned and road ahead
David Akhavan, Darya Alizadeh, Dongrui Wang, et al.
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 60-84
Open Access | Times Cited: 184
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
In-Young Jung, Yoon-Young Kim, Ho-Sung Yu, et al.
Cancer Research (2018) Vol. 78, Iss. 16, pp. 4692-4703
Open Access | Times Cited: 182
Making CAR T Cells a Solid Option for Solid Tumors
Andrea Schmidts, Marcela V. Maus
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 176
Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
Karin Straathof, Barry Flutter, Rebecca Wallace, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 571
Open Access | Times Cited: 162
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
Lynsey M. Whilding, Leena Halim, Benjamin Draper, et al.
Cancers (2019) Vol. 11, Iss. 5, pp. 674-674
Open Access | Times Cited: 159
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Paul Shafer, Lauren Kelly, Valentina Hoyos
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 148
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Louai Labanieh, Robbie G. Majzner, Dorota D. Klysz, et al.
Cell (2022) Vol. 185, Iss. 10, pp. 1745-1763.e22
Open Access | Times Cited: 147
CAR T-Cell Therapy in Hematological Malignancies
Theresa Haslauer, Richard Greil, Nadja Zaborsky, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8996-8996
Open Access | Times Cited: 131
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
Luke Maggs, Giulia Cattaneo, Ali Emre Dal, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 112
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 2, pp. 192-209
Open Access | Times Cited: 102
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Xiaomin Zhang, Hui Zhang, Huixuan Lan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 88
Forks in the road for CAR T and CAR NK cell cancer therapies
Oula K. Dagher, Avery D. Posey
Nature Immunology (2023) Vol. 24, Iss. 12, pp. 1994-2007
Closed Access | Times Cited: 53
Page 1 - Next Page

Scroll to top